-
1
-
-
34447128160
-
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119
-
Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, and Gandara DR (2007) Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol 2:526-530.
-
(2007)
J Thorac Oncol
, vol.2
, pp. 526-530
-
-
Akerley, W.1
McCoy, J.2
Hesketh, P.J.3
Goodwin, J.W.4
Bearden, J.D.5
Atkins, J.N.6
Chansky, K.7
Crowley, J.J.8
Gandara, D.R.9
-
2
-
-
0347993069
-
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress
-
Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, and Karnitz LM (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278:52572-52577.
-
(2003)
J Biol Chem
, vol.278
, pp. 52572-52577
-
-
Arlander, S.J.1
Eapen, A.K.2
Vroman, B.T.3
McDonald, R.J.4
Toft, D.O.5
Karnitz, L.M.6
-
3
-
-
0033368083
-
Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines
-
Bahadori HR, Rocha Lima CM, Green MR, and Safa AR (1999) Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 19:5423-5428.
-
(1999)
Anticancer Res
, vol.19
, pp. 5423-5428
-
-
Bahadori, H.R.1
Rocha Lima, C.M.2
Green, M.R.3
Safa, A.R.4
-
4
-
-
0024847290
-
What is synergy?
-
Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93-141.
-
(1989)
Pharmacol Rev
, vol.41
, pp. 93-141
-
-
Berenbaum, M.C.1
-
5
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
7
-
-
0345688175
-
Nucleoside anticancer drugs: The role of nucleoside transporters in resistance to cancer chemotherapy
-
Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, and Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536.
-
(2003)
Oncogene
, vol.22
, pp. 7524-7536
-
-
Damaraju, V.L.1
Damaraju, S.2
Young, J.D.3
Baldwin, S.A.4
Mackey, J.5
Sawyer, M.B.6
Cass, C.E.7
-
8
-
-
0025133118
-
Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
-
D'Arpa P, Beardmore C, and Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924.
-
(1990)
Cancer Res
, vol.50
, pp. 6919-6924
-
-
D'Arpa, P.1
Beardmore, C.2
Liu, L.F.3
-
9
-
-
17144377827
-
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons
-
Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, and Kaufmann SH (2005) The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 280:14349-14355.
-
(2005)
J Biol Chem
, vol.280
, pp. 14349-14355
-
-
Flatten, K.1
Dai, N.T.2
Vroman, B.T.3
Loegering, D.4
Erlichman, C.5
Karnitz, L.M.6
Kaufmann, S.H.7
-
10
-
-
0024388737
-
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
-
Holm C, Covey JM, Kerrigan D, and Pommier Y (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49:6365-6368.
-
(1989)
Cancer Res
, vol.49
, pp. 6365-6368
-
-
Holm, C.1
Covey, J.M.2
Kerrigan, D.3
Pommier, Y.4
-
11
-
-
0024420685
-
Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
-
Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
-
(1989)
Cancer Res
, vol.49
, pp. 5077-5082
-
-
Hsiang, Y.H.1
Lihou, M.G.2
Liu, L.F.3
-
12
-
-
0029060757
-
Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
-
Huang P and Plunkett W (1995) Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188.
-
(1995)
Cancer Chemother Pharmacol
, vol.36
, pp. 181-188
-
-
Huang, P.1
Plunkett, W.2
-
13
-
-
0036330373
-
A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy
-
Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, and Georgoulias V (2002) A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 22:1891-1896.
-
(2002)
Anticancer Res
, vol.22
, pp. 1891-1896
-
-
Kakolyris, S.S.1
Kouroussis, C.2
Koukourakis, M.3
Kalbakis, K.4
Mavroudis, D.5
Vardakis, N.6
Georgoulias, V.7
-
14
-
-
27844561114
-
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival
-
Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, et al. (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636-1644.
-
(2005)
Mol Pharmacol
, vol.68
, pp. 1636-1644
-
-
Karnitz, L.M.1
Flatten, K.S.2
Wagner, J.M.3
Loegering, D.4
Hackbarth, J.S.5
Arlander, S.J.6
Vroman, B.T.7
Thomas, M.B.8
Baek, Y.U.9
Hopkins, K.M.10
-
15
-
-
0035884184
-
Reutilization of immunoblots after chemiluminescent detection
-
Kaufmann SH (2001) Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 296:283-286.
-
(2001)
Anal Biochem
, vol.296
, pp. 283-286
-
-
Kaufmann, S.H.1
-
16
-
-
0030933933
-
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells
-
Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, and Rowinsky EK (1997) Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 89:2098-2104.
-
(1997)
Blood
, vol.89
, pp. 2098-2104
-
-
Kaufmann, S.H.1
Svingen, P.A.2
Gore, S.D.3
Armstrong, D.K.4
Cheng, Y.C.5
Rowinsky, E.K.6
-
17
-
-
33751272219
-
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
-
Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, and Kalofonos HP (2007) A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol 59:51-59.
-
(2007)
Cancer Chemother Pharmacol
, vol.59
, pp. 51-59
-
-
Kosmas, C.1
Tsavaris, N.2
Syrigos, K.3
Koutras, A.4
Tsakonas, G.5
Makatsoris, T.6
Mylonakis, N.7
Karabelis, A.8
Stathopoulos, G.P.9
Kalofonos, H.P.10
-
18
-
-
0344443643
-
Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro
-
Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, Gore SD, Karp JE, Sebolt-Leopold J, and Kaufmann SH (2003) Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem 278:47326-47339.
-
(2003)
J Biol Chem
, vol.278
, pp. 47326-47339
-
-
Meng, X.W.1
Chandra, J.2
Loegering, D.3
Van Becelaere, K.4
Kottke, T.J.5
Gore, S.D.6
Karp, J.E.7
Sebolt-Leopold, J.8
Kaufmann, S.H.9
-
19
-
-
23044492007
-
Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine
-
Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, and Lawrence TS (2005) Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65:6835-6842.
-
(2005)
Cancer Res
, vol.65
, pp. 6835-6842
-
-
Morgan, M.A.1
Parsels, L.A.2
Parsels, J.D.3
Mesiwala, A.K.4
Maybaum, J.5
Lawrence, T.S.6
-
20
-
-
0031684654
-
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
-
Mullany S, Svingen PA, Kaufmann SH, and Erlichman C (1998) Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 42:391-399.
-
(1998)
Cancer Chemother Pharmacol
, vol.42
, pp. 391-399
-
-
Mullany, S.1
Svingen, P.A.2
Kaufmann, S.H.3
Erlichman, C.4
-
21
-
-
0028204160
-
DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
-
Nelson WG and Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823.
-
(1994)
Mol Cell Biol
, vol.14
, pp. 1815-1823
-
-
Nelson, W.G.1
Kastan, M.B.2
-
22
-
-
37249009181
-
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
-
Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, and Nishio M (2008) Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol 61:503-508.
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 503-508
-
-
Ohyanagi, F.1
Horiike, A.2
Okano, Y.3
Satoh, Y.4
Okumura, S.5
Ishikawa, Y.6
Nakagawa, K.7
Horai, T.8
Nishio, M.9
-
23
-
-
0028799108
-
Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
-
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, and Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 (4 Suppl 11):3-10.
-
(1995)
Semin Oncol
, vol.22
, Issue.4 SUPPL. 11
, pp. 3-10
-
-
Plunkett, W.1
Huang, P.2
Xu, Y.Z.3
Heinemann, V.4
Grunewald, R.5
Gandhi, V.6
-
24
-
-
33749034730
-
Topoisomerase I inhibitors: Camptothecins and beyond
-
Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 789-802
-
-
Pommier, Y.1
-
25
-
-
0036023405
-
Gemcitabine (2′,2′- difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I
-
Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, and Pommier Y (2002) Gemcitabine (2′,2′- difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 8:2499-2504.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 2499-2504
-
-
Pourquier, P.1
Gioffre, C.2
Kohlhagen, G.3
Urasaki, Y.4
Goldwasser, F.5
Hertel, L.W.6
Yu, S.7
Pon, R.T.8
Gmeiner, W.H.9
Pommier, Y.10
-
26
-
-
4644327989
-
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
-
Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, and Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3776-3783
-
-
Rocha Lima, C.M.1
Green, M.R.2
Rotche, R.3
Miller Jr, W.H.4
Jeffrey, G.M.5
Cisar, L.A.6
Morganti, A.7
Orlando, N.8
Gruia, G.9
Miller, L.L.10
-
27
-
-
0036498787
-
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer
-
Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, et al. (2002) Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182-1191.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1182-1191
-
-
Rocha Lima, C.M.1
Savarese, D.2
Bruckner, H.3
Dudek, A.4
Eckardt, J.5
Hainsworth, J.6
Yunus, F.7
Lester, E.8
Miller, W.9
Saville, W.10
-
28
-
-
0002013114
-
Phase I study of CPT-11 and gemcitabine in patients with solid tumors
-
Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, and Green MR (1999) Phase I study of CPT-11 and gemcitabine in patients with solid tumors. Cancer Ther 2:58-66.
-
(1999)
Cancer Ther
, vol.2
, pp. 58-66
-
-
Rocha Lima, C.M.1
Leong, S.S.2
Sherman, C.A.3
Perkel, J.A.4
Putman, T.5
Safa, A.R.6
Green, M.R.7
-
29
-
-
33847304461
-
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902
-
Rocha-Lima CM, Herndon JE 2nd, Lee ME, Atkins JN, Mauer A, Vokes E, and Green MR (2007) Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: cancer and leukemia group B study 39902. Ann Oncol 18:331-337.
-
(2007)
Ann Oncol
, vol.18
, pp. 331-337
-
-
Rocha-Lima, C.M.1
Herndon 2nd, J.E.2
Lee, M.E.3
Atkins, J.N.4
Mauer, A.5
Vokes, E.6
Green, M.R.7
-
30
-
-
0028105119
-
Schedule dependence of sensitivity to 2′,2′- difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
-
Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, and Peters GJ (1994) Schedule dependence of sensitivity to 2′,2′- difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 48:1327-1339.
-
(1994)
Biochem Pharmacol
, vol.48
, pp. 1327-1339
-
-
Ruiz van Haperen, V.W.1
Veerman, G.2
Boven, E.3
Noordhuis, P.4
Vermorken, J.B.5
Peters, G.J.6
-
31
-
-
50449101282
-
Cytidine Analogues
-
Chabner BA and Lango DL eds pp, Lippincott Williams & Wilkins, Baltimore, MD
-
Ryan DP, Garcia-Carbonero R, and Chabner BA (2006) Cytidine Analogues, in Cancer Chemotherapy and Biotherapy (Chabner BA and Lango DL eds) pp 183-211, Lippincott Williams & Wilkins, Baltimore, MD.
-
(2006)
Cancer Chemotherapy and Biotherapy
, pp. 183-211
-
-
Ryan, D.P.1
Garcia-Carbonero, R.2
Chabner, B.A.3
-
32
-
-
34548598180
-
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors
-
Saif MW, Sellers S, Li M, Wang W, Cusimano L, Wang H, and Zhang R (2007) A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 60:871-882.
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 871-882
-
-
Saif, M.W.1
Sellers, S.2
Li, M.3
Wang, W.4
Cusimano, L.5
Wang, H.6
Zhang, R.7
-
33
-
-
20344383750
-
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia
-
Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, and Adams DJ (2005) Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res 11:4225-4233.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4225-4233
-
-
Shanks, R.H.1
Rizzieri, D.A.2
Flowers, J.L.3
Colvin, O.M.4
Adams, D.J.5
-
34
-
-
0035116697
-
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine
-
Shi Z, Azuma A, Sampath D, Li YX, Huang P, and Plunkett W (2001) S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61:1065-1072.
-
(2001)
Cancer Res
, vol.61
, pp. 1065-1072
-
-
Shi, Z.1
Azuma, A.2
Sampath, D.3
Li, Y.X.4
Huang, P.5
Plunkett, W.6
-
35
-
-
0022186670
-
Measurement of protein using bicinchoninic acid
-
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
-
(1985)
Anal Biochem
, vol.150
, pp. 76-85
-
-
Smith, P.K.1
Krohn, R.I.2
Hermanson, G.T.3
Mallia, A.K.4
Gartner, F.H.5
Provenzano, M.D.6
Fujimoto, E.K.7
Goeke, N.M.8
Olson, B.J.9
Klenk, D.C.10
-
36
-
-
34547134312
-
Topoisomerase I-targeting drugs
-
Chabner BA and Longo DL eds pp, Lippincott Williams & Wilkins, Baltimore, MD
-
Sparreboom A and Zamboni WC (2006) Topoisomerase I-targeting drugs, in Cancer Chemotherapy and Biotherapy (Chabner BA and Longo DL eds) pp 371-413, Lippincott Williams & Wilkins, Baltimore, MD.
-
(2006)
Cancer Chemotherapy and Biotherapy
, pp. 371-413
-
-
Sparreboom, A.1
Zamboni, W.C.2
-
37
-
-
33748297529
-
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
-
Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, et al. (2006) A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587-592.
-
(2006)
Br J Cancer
, vol.95
, pp. 587-592
-
-
Stathopoulos, G.P.1
Syrigos, K.2
Aravantinos, G.3
Polyzos, A.4
Papakotoulas, P.5
Fountzilas, G.6
Potamianou, A.7
Ziras, N.8
Boukovinas, J.9
Varthalitis, J.10
-
38
-
-
37049019520
-
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer
-
Sun W, Hewitt MR, Theobald MR, Hershock D, and Haller DG (2007) A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer 110:2768-2774.
-
(2007)
Cancer
, vol.110
, pp. 2768-2774
-
-
Sun, W.1
Hewitt, M.R.2
Theobald, M.R.3
Hershock, D.4
Haller, D.G.5
-
39
-
-
0018198132
-
Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells
-
Wan CW and Mak TW (1978) Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells. Cancer Res 38:2768-2772.
-
(1978)
Cancer Res
, vol.38
, pp. 2768-2772
-
-
Wan, C.W.1
Mak, T.W.2
-
40
-
-
24044476837
-
Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway
-
Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F, and Abraham RT (2005) Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 19:607-618.
-
(2005)
Mol Cell
, vol.19
, pp. 607-618
-
-
Zhang, Y.W.1
Otterness, D.M.2
Chiang, G.G.3
Xie, W.4
Liu, Y.C.5
Mercurio, F.6
Abraham, R.T.7
|